Renovorx announces initial results in pharmacokinetic (pk) substudy: data on renovogem™ supports potential for renovotamp® therapy platform to increase local gemcitabine (chemotherapy) delivery and decrease side effects of pancreatic cancer treatment
Los altos, calif.--( business wire )--renovorx, inc. (nasdaq: rnxt), a biopharmaceutical company focused on the localized treatment of solid tumors, today announced initial results from a pharmacokinetic (pk) substudy within the phase iii un-blinded randomized control tiger-pac clinical trial to be presented at the 2023 asco gastrointestinal (asco gi) cancers symposium this week. the tiger-pac clinical trial is evaluating intra-arterial (ia) administration of gemcitabine (chemotherapy) using the proprietary renovorx trans-arterial micro-perfusion (renovotamp) platform for targeted treatment of locally advanced pancreatic cancer (lapc). the substudy provides clinical support that renovotamp may increase local drug delivery and thus concentration at the tumor site while decreasing the debilitating side effects often associated with systemic intravenous (iv) delivery, which is the current standard of care.
RNXT Ratings Summary
RNXT Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission